Tratamiento del VIH y datos neurológicos destacados de CROI 2023

Dr Monica Gandhi, of University of California, San Francisco, reports on important studies on HIV treatment and neurologic findings presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2023 Annual Meeting.

Dr Gandhi begins by discussing two studies that looked at long-acting therapies. The first was the 12-month results from the SOLAR trial, which indicated that use of the injectable long-acting cabotegravir plus rilpivirine combination proved noninferior in virologic efficacy to the oral antiretroviral therapy (ART) regimen.

Next, Dr Gandhi reviews long-acting subcutaneous lenacapavir. In the CALIBRATE study, lenacapavir combined with two oral antiretroviral agents demonstrated high rates of virologic suppression in all participants who received lenacapavir with an oral backbone.

The next study Dr Gandhi discusses is the D2EFT trial, which examines HIV-1–infected patients whose first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART is failing. The study demonstrated that two simplified treatments, dolutegravir with two NNRTIs or boosted darunavir with NNRTIs, led to high rates of virologic suppression in patients who did not respond to first-line therapies.

Finally, Dr Gandhi reviews results of studies examining the relationship between HIV and stroke, and the effect of HIV treatment on neurocognitive performance.

Source: https://www.medscape.com/recap/986145?src=soc_fb_230314_mscpedt_news_mdscp_recap&faf=1